| Ytd | 233.45% | |
| 1y | 104.09% |
| Open | 4.70 | Prev Close | 4.62 | Low | 4.45 | High | 4.90 | Mkt Cap | 45.65M |
| Vol | 91.75K | Avg Vol | 127.16K | EPS | -1.74 | P/E | N/A | Forward P/E | -0.89 |
| Beta | 0.84 | Short Ratio | 0.76 | Inst. Own | 12.20% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 6.06 | 200-d Avg | 5.21 | 1yr Est | 20.50 |
Gainers Biohaven (NYSE:BHVN) shares increased by 16.5% to $16.75 during Wednesday's regular ses
Gainers Autonomix Medical (NASDAQ:AMIX) stock moved upwards by 142.1% to $13.0 during Monday's
Gainers Circle8 Group (NASDAQ:CIRC) shares increased by 18.2% to $0.77 during Thursday's pre-ma
Edesa Biotech Stock falls in premarket trading as investors weigh a $25 million offering, new warran
TORONTO, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq: EDSA) (the “Company” or “Ede
Gainers BioVie (NASDAQ:BIVI) stock increased by 15.7% to $1.55 during Wednesday's after-market
Edesa Biotech, Inc. (NASDAQ:EDSA) (the "Company" or "Edesa"), a clinical-stage bioph
TORONTO, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq: EDSA) (the “Company” or “Ede
Edesa Biotech (NASDAQ:EDSA) reported quarterly losses of $(0.60) per share which missed the analyst
TORONTO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage bioph
TORONTO, June 11, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq: EDSA) (the “Company” or “Ede
Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company developing host-direct
TORONTO, June 05, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq: EDSA), a clinical-stage biop
TORONTO, May 19, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq: EDSA), a clinical-stage bioph
Edesa Biotech (NASDAQ:EDSA) reported quarterly losses of $(0.49) per share which missed the analyst
TORONTO, May 14, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopha
Selection Follows Positive Phase 3 Results for Paridiprubart Demonstrating Statistically Significant
Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing
TORONTO, March 26, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biop
Box Inc (BOX) shares jump 6.2% in pre-market trading after beating earnings expectations with $305
Results in a population of 278 patients affirm statistically significant mortality reductions
Results in a population of 278 patients affirm statistically significant mortality reductionsBenefit
TORONTO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage bioph
Guru Stock PicksRobert Bruce has made the following transactions:Reduce in NEE by 1.49%Ray Dalio has
Edesa Biotech (NASDAQ:EDSA) reported quarterly losses of $(0.28) per share which beat the analyst co
TORONTO, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage bioph
Edesa Biotech (NASDAQ:EDSA) reported quarterly losses of $(0.32) per share which missed the analyst
TORONTO, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage bioph
HC Wainwright & Co. analyst Yi Chen reiterates Edesa Biotech (NASDAQ:EDSA) with a Buy and mai
TORONTO, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage bioph